منابع مشابه
Oncotype DX: Scientific Publications and Presentations
403 Assay result variability during determination of mismatch repair deficiency status using immunohistochemistry: A transatlantic comparative study. Hutchins G., Gray G., Quirke P. Abstract #491 Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: Impact on qualityadjusted life expectancy and costs. Meropol N.J., Lyman G.H., Chien R...
متن کاملOncotype Dx Results in Multiple Primary Breast Cancers
PURPOSE To determine whether multiple primary breast cancers have similar genetic profiles, specifically Oncotype Dx Recurrence Scores, and whether obtaining Oncotype Dx on each primary breast cancer affects chemotherapy recommendations. METHODS A database of patients with hormone receptor-positive, lymph node-negative, breast cancer was created for those tumors that were sent for Oncotype Dx...
متن کاملThe analytical validation of the Oncotype DX Recurrence Score assay
In vitro diagnostic multivariate index assays are highly complex molecular assays that can provide clinically actionable information regarding the underlying tumour biology and facilitate personalised treatment. These assays are only useful in clinical practice if all of the following are established: analytical validation (i.e., how accurately/reliably the assay measures the molecular characte...
متن کاملLow utility of Oncotype DX® in the clinic
Precision medicine tools are currently making their way into the clinic and being utilized to diagnose, prognose, and individualize cancer care. The multi-gene expression-based assay, Oncotype DX® (ODX), is a genomic tumor profiling tool that determines the expression of 21 tumor- associated genes; it helps determine the risk for distant recurrence and whether chemotherapy is an appropriate cou...
متن کاملSpotlight on the utility of the Oncotype DX® breast cancer assay
The Oncotype DX® assay was developed to address the need for optimizing the selection of adjuvant systemic therapy for patients with estrogen receptor (ER)-positive, lymph node-negative breast cancer. It has ushered in the era of genomic-based personalized cancer care for ER-positive primary breast cancer and is now widely utilized in various parts of the world. Together with several other geno...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Medical and Paediatric Oncology
سال: 2019
ISSN: 0971-5851,0975-2129
DOI: 10.4103/ijmpo.ijmpo_226_19